Transcriptomic analysis identifies lactoferrin-induced quiescent circuits in neonatal macrophages.

human lactoferrin immune tolerance innate immunity macrophage function microbiome mucosal immunity necrotizing enterocolitis neonatal immune system

Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2023
Historique:
received: 11 08 2023
accepted: 18 09 2023
medline: 1 11 2023
pubmed: 23 10 2023
entrez: 23 10 2023
Statut: epublish

Résumé

Upon birth, a hitherto naïve immune system is confronted with a plethora of microbial antigens due to intestinal bacterial colonization. To prevent excessive inflammation and disruption of the epithelial barrier, physiological mechanisms must promote immune-anergy within the neonatal gut. As high concentrations of human lactoferrin (hLF), a transferrin glycoprotein shown to modulate macrophage function, are frequently encountered in colostrum, its direct interaction with intestinal macrophages may satisfy this physiological need. Thus, the primary objective of this study was to investigate transcriptional changes induced by human lactoferrin in neonatal monocyte-derived macrophages. Cord blood-derived monocytes were differentiated with M-CSF in presence or absence of 500 µg/mL hLF for 7 days and afterwards stimulated with 1 ng/mL LPS or left untreated. RNA was then isolated and subjected to microarray analysis. Differentiation of cord blood-derived monocytes in presence of hLF induced a distinct transcriptional program defined by cell cycle arrest in the G2/M phase, induction of IL-4/IL-13-like signaling, altered extracellular matrix interaction, and enhanced propensity for cell-cell interaction. Moreover, near-complete abrogation of transcriptional changes induced by TLR4 engagement with LPS was observed in hLF-treated samples. The global transition towards an M2-like homeostatic phenotype and the acquisition of quiescence elegantly demonstrate the ontogenetical relevance of hLF in attenuating pro-inflammatory signaling within the developing neonatal intestine. The marked anergy towards proinflammatory stimuli such as LPS further underlines the glycoprotein's potential therapeutic relevance.

Identifiants

pubmed: 37868991
doi: 10.3389/fimmu.2023.1276173
pmc: PMC10590118
doi:

Substances chimiques

Lactoferrin EC 3.4.21.-
Lipopolysaccharides 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1276173

Informations de copyright

Copyright © 2023 Eigenschink, Wessely, Dijmarescu, Förster-Waldl, Farr, Kiss, Berger and Wisgrill.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The authors declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.

Références

Front Immunol. 2021 Oct 26;12:743354
pubmed: 34764959
Pediatr Res. 2017 Jan;81(1-1):99-112
pubmed: 27656771
J Immunol. 2012 May 1;188(9):4690-700
pubmed: 22467657
Nat Med. 2017 May 5;23(5):535-536
pubmed: 28475567
Genome Res. 2003 Nov;13(11):2498-504
pubmed: 14597658
Sci Rep. 2019 Feb 4;9(1):1223
pubmed: 30718924
Clin Exp Immunol. 2018 Jun;192(3):315-324
pubmed: 29393509
Nucleic Acids Res. 2013 Jan;41(Database issue):D1228-33
pubmed: 23180781
Mol Cell. 2023 Jan 5;83(1):121-138.e7
pubmed: 36521490
Biomed Pharmacother. 2023 Sep;165:115012
pubmed: 37329710
Emerg Microbes Infect. 2018 Mar 7;7(1):19
pubmed: 29511161
Am J Physiol Gastrointest Liver Physiol. 2012 Jul;303(1):G93-102
pubmed: 22538401
Molecules. 2019 Apr 03;24(7):
pubmed: 30987256
Front Immunol. 2022 Apr 22;13:859398
pubmed: 35529858
J Biol Chem. 2000 Jul 7;275(27):20480-7
pubmed: 10781611
Biometals. 2004 Jun;17(3):209-16
pubmed: 15222467
Cell Mol Life Sci. 2005 Nov;62(22):2560-75
pubmed: 16261254
Nat Commun. 2019 Nov 1;10(1):4997
pubmed: 31676793
Am J Surg. 2012 Apr;203(4):428-35
pubmed: 22450025
Front Immunol. 2021 Feb 12;12:604080
pubmed: 33643310
Biochem Cell Biol. 2006 Jun;84(3):282-90
pubmed: 16936798
J Immunol Res. 2019 Dec 20;2019:2525984
pubmed: 31930146
Sci Rep. 2019 Jun 4;9(1):8262
pubmed: 31164666
Am J Physiol Gastrointest Liver Physiol. 2001 Jun;280(6):G1217-26
pubmed: 11352815
Protein Sci. 2018 Jan;27(1):233-244
pubmed: 28940711
Front Immunol. 2019 Mar 27;10:583
pubmed: 30972074
J Immunol. 2012 Oct 1;189(7):3439-48
pubmed: 22925925
Int J Mol Sci. 2021 Oct 19;22(20):
pubmed: 34681923
Nucleic Acids Res. 2023 Jan 6;51(D1):D638-D646
pubmed: 36370105
Cancer Res. 1996 Oct 15;56(20):4590-4
pubmed: 8840967
Nucleic Acids Res. 2016 Jan 4;44(D1):D457-62
pubmed: 26476454
Sci Data. 2018 Feb 27;5:180015
pubmed: 29485622
Nat Commun. 2020 Nov 13;11(1):5794
pubmed: 33188181
Gut. 2015 Apr;64(4):589-600
pubmed: 24848264
Biochem Soc Trans. 2021 Nov 1;49(5):2371-2380
pubmed: 34581755
Ann Clin Biochem. 1989 Sep;26 ( Pt 5):407-11
pubmed: 2683971
FEBS J. 2010 May;277(9):2051-66
pubmed: 20345905
Cell Rep. 2019 Feb 5;26(6):1627-1640.e7
pubmed: 30726743
Gastroenterology. 2011 Jan;140(1):242-53
pubmed: 20875417
Acta Pharmacol Sin. 2014 May;35(5):557-66
pubmed: 24786230
Proc Natl Acad Sci U S A. 2002 Feb 5;99(3):1503-8
pubmed: 11805289
Gastroenterology. 2020 Dec;159(6):2130-2145.e5
pubmed: 32805279
Proc Natl Acad Sci U S A. 1997 Oct 28;94(22):12075-80
pubmed: 9342365
Glycoconj J. 2002 May-Jun;19(4-5):315-8
pubmed: 12975610
Bioinformatics. 2015 Sep 1;31(17):2912-4
pubmed: 25964631
J Surg Res. 2015 Jul;197(1):126-38
pubmed: 25913486
Comp Biochem Physiol B Biochem Mol Biol. 2005 Oct;142(2):129-41
pubmed: 16111909
Proc Natl Acad Sci U S A. 1987 Apr;84(7):1769-73
pubmed: 3470756
Cell Chem Biol. 2018 Apr 19;25(4):483-493.e9
pubmed: 29478905
Am J Gastroenterol. 2002 Aug;97(8):2000-4
pubmed: 12190167
Commun Biol. 2022 Jan 11;5(1):31
pubmed: 35017649
Mucosal Immunol. 2014 May;7(3):730-40
pubmed: 24220298
J Leukoc Biol. 2006 Sep;80(3):492-9
pubmed: 16793909
BMC Bioinformatics. 2011 Jan 26;12:35
pubmed: 21269502
PLoS One. 2013 Sep 04;8(9):e73277
pubmed: 24023849
Front Immunol. 2021 Oct 25;12:767456
pubmed: 34759934

Auteurs

Michael Eigenschink (M)

Division of Neonatology, Pediatric Intensive Care and Neuropaediatrics, Department of Pediatrics and Adolescent Medicine, Comprehensive Center for Pediatrics, Medical University of Vienna, Vienna, Austria.

Isabelle Wessely (I)

Division of Neonatology, Pediatric Intensive Care and Neuropaediatrics, Department of Pediatrics and Adolescent Medicine, Comprehensive Center for Pediatrics, Medical University of Vienna, Vienna, Austria.

Marco Dijmarescu (M)

Division of Neonatology, Pediatric Intensive Care and Neuropaediatrics, Department of Pediatrics and Adolescent Medicine, Comprehensive Center for Pediatrics, Medical University of Vienna, Vienna, Austria.

Elisabeth Förster-Waldl (E)

Division of Neonatology, Pediatric Intensive Care and Neuropaediatrics, Department of Pediatrics and Adolescent Medicine, Comprehensive Center for Pediatrics, Medical University of Vienna, Vienna, Austria.

Alex Farr (A)

Department of Obstetrics and Gynecology, Division of Obstetrics and Feto-Maternal Medicine, Comprehensive Center for Pediatrics, Medical University of Vienna, Vienna, Austria.

Herbert Kiss (H)

Department of Obstetrics and Gynecology, Division of Obstetrics and Feto-Maternal Medicine, Comprehensive Center for Pediatrics, Medical University of Vienna, Vienna, Austria.

Angelika Berger (A)

Division of Neonatology, Pediatric Intensive Care and Neuropaediatrics, Department of Pediatrics and Adolescent Medicine, Comprehensive Center for Pediatrics, Medical University of Vienna, Vienna, Austria.

Lukas Wisgrill (L)

Division of Neonatology, Pediatric Intensive Care and Neuropaediatrics, Department of Pediatrics and Adolescent Medicine, Comprehensive Center for Pediatrics, Medical University of Vienna, Vienna, Austria.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH